Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year High – Here’s What Happened

Posted by Brenda Bartman on Aug 24th, 2026

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $84.79 and last traded at $84.7950, with a volume of 184792 shares traded. The stock had previously closed at $84.69.

Analyst Upgrades and Downgrades

CRNX has been the topic of a number of recent analyst reports. Lifesci Capital lowered shares of Crinetics Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen upgraded shares of Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. JonesTrading downgraded shares of Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating and set a $85.00 target price on the stock. in a report on Tuesday, July 7th. Jefferies Financial Group downgraded shares of Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating and lifted their target price for the stock from $55.00 to $85.00 in a report on Tuesday, July 7th. Finally, TD Cowen cut shares of Crinetics Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 8th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Crinetics Pharmaceuticals has a consensus rating of “Hold” and an average price target of $81.00.

Get Our Latest Analysis on CRNX

Crinetics Pharmaceuticals Price Performance

The company has a market capitalization of $8.99 billion, a price-to-earnings ratio of -16.82 and a beta of 0.12. The business has a fifty day moving average price of $69.05 and a 200 day moving average price of $49.42.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.04. The business had revenue of $25.12 million for the quarter, compared to the consensus estimate of $14.84 million. Crinetics Pharmaceuticals had a negative net margin of 1,189.88% and a negative return on equity of 44.22%. Crinetics Pharmaceuticals’s quarterly revenue was up 2336.9% on a year-over-year basis. During the same quarter last year, the company posted ($1.23) earnings per share. As a group, sell-side analysts predict that Crinetics Pharmaceuticals, Inc. will post -4.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, Director Coelho Rogerio Vivaldi sold 3,000 shares of the company’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the transaction, the director owned 19,225 shares of the company’s stock, valued at approximately $769,000. This represents a 13.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 6,900 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total transaction of $246,123.00. Following the completion of the sale, the director owned 6,400 shares of the company’s stock, valued at approximately $228,288. The trade was a 51.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Parkman Healthcare Partners LLC raised its stake in shares of Crinetics Pharmaceuticals by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 73,725 shares of the company’s stock worth $3,071,000 after acquiring an additional 313 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Crinetics Pharmaceuticals by 34.6% in the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock valued at $57,000 after purchasing an additional 315 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Crinetics Pharmaceuticals by 107.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock valued at $30,000 after purchasing an additional 331 shares in the last quarter. Brooklyn Investment Group raised its position in Crinetics Pharmaceuticals by 6.3% in the 4th quarter. Brooklyn Investment Group now owns 5,890 shares of the company’s stock worth $280,000 after purchasing an additional 348 shares during the last quarter. Finally, Commerce Bank raised its position in Crinetics Pharmaceuticals by 5.9% in the 4th quarter. Commerce Bank now owns 8,019 shares of the company’s stock worth $373,000 after purchasing an additional 444 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company’s stock.

Crinetics Pharmaceuticals Company Profile

(Get Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.